HAE focus tightens as trial and pediatric milestones hit
- ORLADEYO drives the business, generating $148.3 million in net revenue for Q1 2026.
- The pediatric ORLADEYO manufacturing delay is resolved and product is shipping.
- Management completed navenibart trial enrollment ahead of schedule in June 2026.
- A new European licensing deal for navenibart brought in $70 million upfront.
- The main worry remains heavy reliance on a single disease market and patent fight.
A sharper HAE bet
BioCryst has become a highly focused HAE company. Hereditary angioedema is a rare disease that causes sudden swelling attacks. ORLADEYO, its once-daily oral drug, is commercial and produced $148.3 million of net revenue in Q1 2026.
The bull case is simple and gaining momentum. ORLADEYO keeps growing, navenibart gives BioCryst a long-acting injectable option, and the company can offer patients two different ways to prevent HAE attacks. The pediatric launch delay is fully resolved with shipments underway, and navenibart trial enrollment finished ahead of schedule.
The bear case remains tied to concentration risk. BioCryst is deeply invested in HAE after buying Astria. It also took on a new $400 million term loan tied to that deal. If ORLADEYO slows, navenibart disappoints in late 2027, or the ORLADEYO patent litigation goes badly, the company has few fallback options.
Investors should watch pediatric ORLADEYO retention, navenibart topline data in Q3 2027, ORLADEYO revenue against guidance, and any developments in the Annora patent case.
One commercial engine funds the buildout
BioCryst makes money primarily by selling ORLADEYO. After selling its European ORLADEYO business in 2025, the company is more focused on the U.S. market, which management expects will account for about 80 percent of peak global revenue.
The Astria acquisition shifted the model from an oral ORLADEYO story to a broader HAE franchise. By owning navenibart, a long-acting injectable candidate, BioCryst hopes to capture patients who prefer injectables.
Partners help fund this plan. In May 2026, BioCryst licensed European rights for navenibart to Neopharmed for $70.0 million upfront, with up to $275.0 million in future milestones plus royalties. To scale better in the U.S., the company is shifting to a sole-source specialty pharmacy in Q3 2026.
This model requires ORLADEYO cash flow to support debt and launches. It also relies on the company saving money by closing its Birmingham research facility by the end of 2026, lowering operating cost guidance.
Oral now, injectable next
ORLADEYO
ORLADEYO is a once-daily oral drug used to prevent HAE attacks. It generated $148.3 million of net revenue in Q1 2026.
Pediatric ORLADEYO granules
This oral granule version was approved for children ages 2 to 11. The manufacturing delay is fixed, and shipments began in August 2026.
Navenibart
Navenibart is an injectable HAE candidate acquired with Astria. The ALPHA-ORBIT trial completed enrollment in June 2026, with data expected in Q3 2027.
BCX17725
BCX17725 is in Phase 1 testing for Netherton Syndrome. BioCryst expects clinical data from patient cohorts by the end of 2026.
STAR-0310
STAR-0310 is a monoclonal antibody for atopic dermatitis that came from Astria. BioCryst plans to seek strategic alternatives for this asset.
Revenue is still mostly ORLADEYO
BioCryst reports one operating segment. For Q1 2026, ORLADEYO product revenue was $148.3 million of total revenue of $156.4 million, with the rest mainly coming from license and other revenue.
What could break the thesis
ORLADEYO patent loss
High impact · Medium oddsAnnora filed a challenge seeking approval for a generic ORLADEYO before four Orange Book patents expire in 2039. A bad outcome in Delaware court could open the door to earlier generic competition in the U.S.
Navenibart trial stumble
High impact · Medium oddsThe dual oral and injectable HAE strategy only works if navenibart advances cleanly. Any delay or poor clinical data in 2027 would weaken the entire HAE franchise plan.
Debt limits flexibility
Medium impact · Medium oddsBioCryst carries a $400 million Blackstone term loan secured by substantially all assets. This raises pressure on ORLADEYO cash flow and may limit choices if trials slip.
Pediatric ORLADEYO retention
Medium impact · Medium oddsThe manufacturing delay for pediatric ORLADEYO is fixed and initial demand was strong. The focus is now on whether patients stay on the therapy long term.
HAE market competition
Medium impact · High oddsRivals have approved and pipeline HAE drugs. BioCryst must prove patients want both ORLADEYO and navenibart. If competitors win share or force prices down, the franchise could suffer.
In one breath
What does BioCryst Pharmaceuticals do?
BioCryst develops and sells rare-disease drugs. Its main product is ORLADEYO, an oral medicine used to prevent HAE attacks.
Why did BioCryst buy Astria Therapeutics?
Astria added navenibart, a long-acting injectable HAE drug candidate. BioCryst wants to offer both an oral and injectable option for HAE prevention.
What is the status of the pediatric ORLADEYO launch?
The manufacturing delay is fully resolved. The company began shipping the product to children in August 2026 and saw strong initial prescription demand.
What should investors watch next for BCRX?
Key items include navenibart trial data expected in Q3 2027, pediatric ORLADEYO retention, execution of the sole-source pharmacy shift, and the Annora patent litigation.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- August 30, 2026
- Score data
- September 27, 2026
- Reviewed by
- Shivam Bharuka
Comparable Drug Manufacturers - Specialty & Generic companies
Companies near BioCryst Pharmaceuticals, Inc. in Finn's Drug Manufacturers - Specialty & Generic industry ranking.
